

Hironori Nakagami

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9333278/publications.pdf>

Version: 2024-02-01

148
papers

6,497
citations

101384

36
h-index

71532

76
g-index

161
all docs

161
docs citations

161
times ranked

9549
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel Autologous Cell Therapy in Ischemic Limb Disease Through Growth Factor Secretion by Cultured Adipose Tissue-Derived Stromal Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 2542-2547.	1.1	534
2	Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. <i>Journal of Clinical Investigation</i> , 2001, 108, 1429-1437.	3.9	429
3	Adipose Tissue-Derived Stromal Cells as a Novel Option for Regenerative Cell Therapy. <i>Journal of Atherosclerosis and Thrombosis</i> , 2006, 13, 77-81.	0.9	326
4	Angiotensin II accelerates osteoporosis by activating osteoclasts. <i>FASEB Journal</i> , 2008, 22, 2465-2475.	0.2	243
5	NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. <i>Journal of Molecular and Cellular Cardiology</i> , 2003, 35, 851-859.	0.9	241
6	NF- κ B Is a Key Mediator of Cerebral Aneurysm Formation. <i>Circulation</i> , 2007, 116, 2830-2840.	1.6	218
7	Essential Role for miR-196a in Brown Adipogenesis of White Fat Progenitor Cells. <i>PLoS Biology</i> , 2012, 10, e1001314.	2.6	209
8	An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. <i>Cell</i> , 2021, 184, 3452-3466.e18.	13.5	205
9	Therapeutic Angiogenesis Induced by Human Hepatocyte Growth Factor Gene in Rat Diabetic Hind Limb Ischemia Model. <i>Circulation</i> , 2001, 104, 2344-2350.	1.6	184
10	Potential Contribution of a Novel Antifibrotic Factor, Hepatocyte Growth Factor, to Prevention of Myocardial Fibrosis by Angiotensin II Blockade in Cardiomyopathic Hamsters. <i>Circulation</i> , 2000, 102, 246-252.	1.6	182
11	Hypoxia-Induced Endothelial Apoptosis Through Nuclear Factor- κ B (NF- κ B)-Mediated bcl-2 Suppression. <i>Circulation Research</i> , 2000, 86, 974-981.	2.0	177
12	Estrogen Inhibits Vascular Calcification via Vascular RANKL System. <i>Circulation Research</i> , 2010, 107, 466-475.	2.0	173
13	Phosphorylation of p38 Mitogen-Activated Protein Kinase Downstream of Bax-Caspase-3 Pathway Leads to Cell Death Induced by High d-Glucose in Human Endothelial Cells. <i>Diabetes</i> , 2001, 50, 1472-1481.	0.3	147
14	Mitogenic and Antiapoptotic Actions of Hepatocyte Growth Factor Through ERK, STAT3, and Akt in Endothelial Cells. <i>Hypertension</i> , 2001, 37, 581-586.	1.3	146
15	Magnetic nanoparticles with surface modification enhanced gene delivery of HVJ-E vector. <i>Biochemical and Biophysical Research Communications</i> , 2005, 334, 1121-1126.	1.0	144
16	Ribozyme Oligonucleotides Against Transforming Growth Factor- β Inhibited Neointimal Formation After Vascular Injury in Rat Model. <i>Circulation</i> , 2000, 102, 1308-1314.	1.6	97
17	Transfection of Human Hepatocyte Growth Factor Gene Ameliorates Secondary Lymphedema via Promotion of Lymphangiogenesis. <i>Circulation</i> , 2006, 114, 1177-1184.	1.6	93
18	OPG/RANKL/RANK axis is a critical inflammatory signaling system in ischemic brain in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 8191-8196.	3.3	93

#	ARTICLE	IF	CITATIONS
19	Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice. <i>Nature Aging</i> , 2021, 1, 1117-1126.	5.3	87
20	PITAVASTATIN SUPPRESSES FORMATION AND PROGRESSION OF CEREBRAL ANEURYSMS THROUGH INHIBITION OF THE NUCLEAR FACTOR κ B PATHWAY. <i>Neurosurgery</i> , 2009, 64, 357-366.	0.6	79
21	Hepatocyte Growth Factor Prevents Endothelial Cell Death Through Inhibition of bax Translocation From Cytosol to Mitochondrial Membrane. <i>Diabetes</i> , 2002, 51, 2604-2611.	0.3	73
22	Ubiquitin Carboxyl-Terminal Hydrolase L1, a Novel Deubiquitinating Enzyme in the Vasculature, Attenuates NF- κ B Activation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 2184-2190.	1.1	66
23	Estrogen Activates Phosphatases and Antagonizes Growth-Promoting Effect of Angiotensin II. <i>Hypertension</i> , 2002, 39, 41-45.	1.3	65
24	The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice. <i>Nature Communications</i> , 2020, 11, 2482.	5.8	64
25	The Transcription Factors Tbx18 and Wt1 Control the Epicardial Epithelial-Mesenchymal Transition through Bi-Directional Regulation of Slug in Murine Primary Epicardial Cells. <i>PLoS ONE</i> , 2013, 8, e57829.	1.1	63
26	Prevention of osteoporosis by angiotensin-converting enzyme inhibitor in spontaneous hypertensive rats. <i>Hypertension Research</i> , 2009, 32, 786-790.	1.5	59
27	Cross-Talk of Receptor Activator of Nuclear Factor- κ B Ligand Signaling With Renin-Angiotensin System in Vascular Calcification. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 1287-1296.	1.1	53
28	Zyxin Mediates Actin Fiber Reorganization in Epithelial-Mesenchymal Transition and Contributes to Endocardial Morphogenesis. <i>Molecular Biology of the Cell</i> , 2009, 20, 3115-3124.	0.9	48
29	Tumor Necrosis Factor- α Inhibits Growth Factor-Mediated Cell Proliferation Through SHP-1 Activation in Endothelial Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 238-242.	1.1	47
30	Vascular protective effects of ezetimibe in ApoE-deficient mice. <i>Atherosclerosis</i> , 2009, 203, 51-58.	0.4	47
31	Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin/kexin type 9 (PCSK9) epitope in mice. <i>PLoS ONE</i> , 2018, 13, e0191895.	1.1	46
32	Oxidized LDL (oxLDL) activates the angiotensin II type 1 receptor by binding to the lectin-like oxLDL receptor. <i>FASEB Journal</i> , 2015, 29, 3342-3356.	0.2	44
33	Decrease in Blood Pressure and Regression of Cardiovascular Complications by Angiotensin II Vaccine in Mice. <i>PLoS ONE</i> , 2013, 8, e60493.	1.1	44
34	Novel Anti-Microbial Peptide SR-0379 Accelerates Wound Healing via the PI3 Kinase/Akt/mTOR Pathway. <i>PLoS ONE</i> , 2014, 9, e92597.	1.1	43
35	Involvement of Bradykinin and Nitric Oxide in Leptin-Mediated Glucose Uptake in Skeletal Muscle. <i>Endocrinology</i> , 2001, 142, 608-612.	1.4	42
36	HIG1, a novel regulator of mitochondrial β -secretase, maintains normal mitochondrial function. <i>FASEB Journal</i> , 2012, 26, 2306-2317.	0.2	39

#	ARTICLE	IF	CITATIONS
37	Therapeutic vaccine against DPP4 improves glucose metabolism in mice. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E1256-63.	3.3	39
38	Role of Central Nervous System Periostin in Cerebral Ischemia. Stroke, 2012, 43, 1108-1114.	1.0	37
39	Long-Term Reduction of High Blood Pressure by Angiotensin II DNA Vaccine in Spontaneously Hypertensive Rats. Hypertension, 2015, 66, 167-174.	1.3	37
40	Angiotensin-converting enzyme 2 deficiency accelerates and angiotensin 1 restores age-related muscle weakness in mice. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 975-986.	2.9	37
41	Low alpha-synuclein levels in the blood are associated with insulin resistance. Scientific Reports, 2015, 5, 12081.	1.6	36
42	Transfection of Antisense p53 Tumor Suppressor Gene Oligodeoxynucleotides Into Rat Carotid Artery Results in Abnormal Growth of Vascular Smooth Muscle Cells. Circulation, 2000, 101, 1447-1452.	1.6	35
43	New Treatment of Periodontal Diseases by Using NF- κ B Decoy Oligodeoxynucleotides via Prevention of Bone Resorption and Promotion of Wound Healing. Antioxidants and Redox Signaling, 2009, 11, 2065-2075.	2.5	35
44	Teneligliptin: expectations for its pleiotropic action. Expert Opinion on Pharmacotherapy, 2015, 16, 417-426.	0.9	35
45	Therapeutic Vaccine Against S100A9 (S100 Calcium-Binding Protein A9) Inhibits Thrombosis Without Increasing the Risk of Bleeding in Ischemic Stroke in Mice. Hypertension, 2018, 72, 1355-1364.	1.3	35
46	Potential Role of CYLD (Cylindromatosis) as a Deubiquitinating Enzyme in Vascular Cells. American Journal of Pathology, 2008, 172, 818-829.	1.9	34
47	The Mechanism of White and Brown Adipocyte Differentiation. Diabetes and Metabolism Journal, 2013, 37, 85.	1.8	34
48	The dipeptidyl peptidase-4 inhibitor teneligliptin improved endothelial dysfunction and insulin resistance in the SHR/NDmcr-cp rat model of metabolic syndrome. Hypertension Research, 2014, 37, 629-635.	1.5	34
49	Alpha-synuclein elicits glucose uptake and utilization in adipocytes through the Gab1/PI3K/Akt transduction pathway. Cellular and Molecular Life Sciences, 2013, 70, 1123-1133.	2.4	33
50	FHL-2 Suppresses VEGF-Induced Phosphatidylinositol 3-Kinase/Akt Activation via Interaction With Sphingosine Kinase-1. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 909-914.	1.1	32
51	Inorganic polyphosphate differentiates human mesenchymal stem cells into osteoblastic cells. Journal of Bone and Mineral Metabolism, 2010, 28, 418-423.	1.3	32
52	Gene Polymorphism of Myospryn (Cardiomyopathy-Associated 5) Is Associated with Left Ventricular Wall Thickness in Patients with Hypertension. Hypertension Research, 2007, 30, 1239-1246.	1.5	31
53	Model of Vasculogenesis from Embryonic Stem Cells for Vascular Research and Regenerative Medicine. Hypertension, 2006, 48, 112-119.	1.3	30
54	Angiotensin II Peptide Vaccine Protects Ischemic Brain Through Reducing Oxidative Stress. Stroke, 2017, 48, 1362-1368.	1.0	29

#	ARTICLE	IF	CITATIONS
55	A Novel Therapeutic Peptide as a Partial Agonist of RANKL in Ischemic Stroke. <i>Scientific Reports</i> , 2016, 6, 38062.	1.6	28
56	Anti-apoptotic action of hepatocyte growth factor through mitogen-activated protein kinase on human aortic endothelial cells. <i>Journal of Hypertension</i> , 2000, 18, 1411-1420.	0.3	27
57	Development of a novel antimicrobial peptide, AG30, with angiogenic properties. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 535-546.	1.6	27
58	Modification of a novel angiogenic peptide, AG30, for the development of novel therapeutic agents. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 1629-1639.	1.6	26
59	SARS-CoV-2-induced humoral immunity through B cell epitope analysis in COVID-19 infected individuals. <i>Scientific Reports</i> , 2021, 11, 5934.	1.6	26
60	Increase in nuclease resistance and incorporation of NF- κ B decoy oligodeoxynucleotides by modification of the 3' terminus. <i>Journal of Gene Medicine</i> , 2007, 9, 812-819.	1.4	25
61	A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction. <i>Scientific Reports</i> , 2017, 7, 43920.	1.6	25
62	Stable Immune Response Induced by Intradermal DNA Vaccination by a Novel Needleless Pyro-Drive Jet Injector. <i>AAPS PharmSciTech</i> , 2020, 21, 19.	1.5	25
63	Identification of conserved SARS-CoV-2 spike epitopes that expand public cTfh clonotypes in mild COVID-19 patients. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	24
64	The Biphasic Effects of Oxidized-Low Density Lipoprotein on the Vasculogenic Function of Endothelial Progenitor Cells. <i>PLoS ONE</i> , 2015, 10, e0123971.	1.1	22
65	RANKL system in vascular and valve calcification with aging. <i>Inflammation and Regeneration</i> , 2016, 36, 10.	1.5	22
66	Cilnidipine, but not amlodipine, ameliorates osteoporosis in ovariectomized hypertensive rats through inhibition of the N-type calcium channel. <i>Hypertension Research</i> , 2012, 35, 77-81.	1.5	21
67	Recent Advances in Therapeutic Vaccines to Treat Hypertension. <i>Hypertension</i> , 2018, 72, 1031-1036.	1.3	20
68	Temporal and spatial profile of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) in ischemic stroke in mice. <i>PLoS ONE</i> , 2019, 14, e0215482.	1.1	20
69	Cellular senescence and senescence-associated T cells as a potential therapeutic target. <i>Geriatrics and Gerontology International</i> , 2020, 20, 97-100.	0.7	20
70	Time gap between the onset and diagnosis in Werner syndrome: a nationwide survey and the 2020 registry in Japan. <i>Aging</i> , 2020, 12, 24940-24956.	1.4	20
71	Effect of angiotensin receptor blocker, olmesartan, on turnover of bone metabolism in bedridden elderly hypertensive women with disuse syndrome. <i>Geriatrics and Gerontology International</i> , 2015, 15, 1064-1072.	0.7	19
72	Development of COVID-19 vaccines utilizing gene therapy technology. <i>International Immunology</i> , 2021, 33, 521-527.	1.8	19

#	ARTICLE	IF	CITATIONS
73	Anti-Oxidant Gene Therapy by NFκB Decoy Oligodeoxynucleotide. <i>Current Pharmaceutical Biotechnology</i> , 2006, 7, 95-100.	0.9	16
74	Fluvastatin improves osteoporosis in fructose-fed insulin resistant model rats through blockade of the classical mevalonate pathway and antioxidant action. <i>International Journal of Molecular Medicine</i> , 2009, 23, 581-8.	1.8	16
75	Cold shock domain protein A (CSDA) overexpression inhibits tumor growth and lymph node metastasis in a mouse model of squamous cell carcinoma. <i>Clinical and Experimental Metastasis</i> , 2010, 27, 539-547.	1.7	16
76	Development of novel DNA vaccine for VEGF in murine cancer model. <i>Scientific Reports</i> , 2013, 3, 3380.	1.6	16
77	Therapeutic Vaccines for Hypertension and Dyslipidemia. <i>International Heart Journal</i> , 2014, 55, 96-100.	0.5	16
78	Glial fibrillary acidic protein (GFAP) is a novel biomarker for the prediction of autoimmune diabetes. <i>FASEB Journal</i> , 2017, 31, 4053-4063.	0.2	16
79	Development of a novel RANKL-based peptide, microglial healing peptide1-AcN (MHP1-AcN), for treatment of ischemic stroke. <i>Scientific Reports</i> , 2018, 8, 17770.	1.6	16
80	Progress of Gene Therapy in Cardiovascular Disease. <i>Hypertension</i> , 2020, 76, 1038-1044.	1.3	16
81	Novel Drug Delivery System by Surface Modified Magnetic Nanoparticles. <i>Journal of Nanoscience and Nanotechnology</i> , 2006, 6, 3269-3276.	0.9	16
82	Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia. <i>Cell Reports Medicine</i> , 2021, 2, 100446.	3.3	16
83	Do Angiotensin Receptor Blockers Protect Against Alzheimer's Disease?. <i>Drugs and Aging</i> , 2013, 30, 367-372.	1.3	15
84	Long-term expression of periostin during the chronic stage of ischemic stroke in mice. <i>Hypertension Research</i> , 2014, 37, 494-499.	1.5	15
85	New Concept of Vascular Calcification and Metabolism. <i>Current Vascular Pharmacology</i> , 2011, 9, 124-127.	0.8	14
86	Potential Effect of Angiotensin II Receptor Blockade in Adipose Tissue and Bone. <i>Current Pharmaceutical Design</i> , 2013, 19, 3049-3053.	0.9	14
87	Combined Analysis of Clinical Data on HGF Gene Therapy to Treat Critical Limb Ischemia in Japan. <i>Current Gene Therapy</i> , 2020, 20, 25-35.	0.9	14
88	Development of High-Throughput Functional Screening of Therapeutic Genes, Using a Hemagglutinating Virus of Japan Envelope Vector. <i>Human Gene Therapy</i> , 2006, 17, 470-475.	1.4	13
89	Obesity and Gastrointestinal Hormones-Dual Effect of Angiotensin II Receptor Blockade and a Partial Agonist of PPAR-γ. <i>Current Vascular Pharmacology</i> , 2011, 9, 162-166.	0.8	13
90	Prevention of Neointimal Formation After Angioplasty Using Nuclear Factor-κB Decoy Oligodeoxynucleotide-Coated Balloon Catheter in Rabbit Model. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 787-796.	1.4	13

#	ARTICLE	IF	CITATIONS
91	Dysfunctional high density lipoprotein failed to rescue the function of oxidized low density lipoprotein-treated endothelial progenitor cells: a novel index for the prediction of HDL functionality. <i>Translational Research</i> , 2019, 205, 17-32.	2.2	13
92	Continuous infusion of angiotensin II modulates hypertrophic differentiation and apoptosis of chondrocytes in cartilage formation in a fracture model mouse. <i>Hypertension Research</i> , 2015, 38, 382-393.	1.5	12
93	Involvement of Bradykinin and Nitric Oxide in Leptin-Mediated Glucose Uptake in Skeletal Muscle. , 0, .		12
94	Nifedipine prevents hepatic fibrosis in a non-alcoholic steatohepatitis model induced by an L-methionine-and choline-deficient diet. <i>Molecular Medicine Reports</i> , 2011, 5, 37-40.	1.1	11
95	Involvement of β -secretase in postnatal angiogenesis. <i>Biochemical and Biophysical Research Communications</i> , 2007, 363, 584-590.	1.0	10
96	Association between renin-angiotensin-aldosterone system blockade and future osteoporotic fracture risk in hypertensive population. <i>Medicine (United States)</i> , 2017, 96, e8331.	0.4	10
97	Preventative effects of the partial RANKL peptide MHP1-AcN in a mouse model of imiquimod-induced psoriasis. <i>Scientific Reports</i> , 2019, 9, 15434.	1.6	10
98	Antiproliferative Effects of Monoclonal Antibodies against (Pro)Renin Receptor in Pancreatic Ductal Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1844-1855.	1.9	10
99	Management guideline for Werner syndrome 2020. 6. Skin ulcers associated with Werner syndrome: Prevention and non-surgical and surgical treatment. <i>Geriatrics and Gerontology International</i> , 2021, 21, 153-159.	0.7	10
100	Therapeutic Vaccines for Hypertension: a New Option for Clinical Practice. <i>Current Hypertension Reports</i> , 2018, 20, 22.	1.5	9
101	Preclinical study of a DNA vaccine targeting SARS-CoV-2. <i>Current Research in Translational Medicine</i> , 2022, 70, 103348.	1.2	9
102	Physician-initiated clinical study of limb ulcers treated with a functional peptide, SR-0379: from discovery to a randomized, double-blind, placebo-controlled trial. <i>Npj Aging and Mechanisms of Disease</i> , 2018, 4, 2.	4.5	8
103	Therapeutic Effects of Systemic Administration of the Novel RANKL-Modified Peptide, MHP1, for Ischemic Stroke in Mice. <i>BioMed Research International</i> , 2018, 2018, 1-8.	0.9	8
104	Management guideline for Werner syndrome 2020. 3. Diabetes associated with Werner syndrome. <i>Geriatrics and Gerontology International</i> , 2021, 21, 142-145.	0.7	8
105	Brief report on a phase I/IIa study to assess the safety, tolerability, and immune response of AGMG0201 in patients with essential hypertension. <i>Hypertension Research</i> , 2022, 45, 61-65.	1.5	8
106	Prevention of Progression of Aortic Aneurysm by Peptide Vaccine Against Ang II (Angiotensin II) in a Rat Model. <i>Hypertension</i> , 2020, 76, 1879-1888.	1.3	7
107	Therapeutic vaccine for chronic diseases after the COVID-19 Era. <i>Hypertension Research</i> , 2021, 44, 1047-1053.	1.5	7
108	Peptide Vaccines for Hypertension and Diabetes Mellitus. <i>Vaccines</i> , 2014, 2, 832-840.	2.1	6

#	ARTICLE	IF	CITATIONS
109	Physician-initiated first-in-human clinical study using a novel angiogenic peptide, AG30/5C, for patients with severe limb ulcers. <i>Geriatrics and Gerontology International</i> , 2017, 17, 2150-2156.	0.7	6
110	Management guideline for Werner syndrome 2020. 4. Osteoporosis associated with Werner syndrome. <i>Geriatrics and Gerontology International</i> , 2021, 21, 146-149.	0.7	6
111	Investigator-initiated clinical study of a functional peptide, SR0379, for limb ulcers of patients with Werner syndrome as a pilot study. <i>Geriatrics and Gerontology International</i> , 2019, 19, 1118-1123.	0.7	6
112	Links Between Hypertension and Osteoporosis: Benidipine Ameliorates Osteoporosis in Ovariectomized Hypertensive Rats Through Promotion of Osteoblast Proliferation and Inhibition of Osteoclast Differentiation. <i>Current Cardiovascular Risk Reports</i> , 2012, 6, 274-280.	0.8	5
113	Design of therapeutic vaccines as a novel antibody therapy for cardiovascular diseases. <i>Journal of Cardiology</i> , 2017, 70, 201-205.	0.8	5
114	Evaluating the potential of the GFAP-KLH immune-tolerizing vaccine for type 1 diabetes in mice. <i>FEBS Letters</i> , 2017, 591, 129-136.	1.3	5
115	Management guideline for Werner syndrome 2020. 7. Skin ulcer associated with Werner syndrome: Dermatological treatment. <i>Geriatrics and Gerontology International</i> , 2021, 21, 160-162.	0.7	5
116	Management guideline for Werner syndrome 2020 8. Calcification in tendons associated with Werner syndrome. <i>Geriatrics and Gerontology International</i> , 2021, 21, 163-165.	0.7	5
117	Management guideline for Werner syndrome 2020. 2. Sarcopenia associated with Werner syndrome. <i>Geriatrics and Gerontology International</i> , 2021, 21, 139-141.	0.7	5
118	Prevention of Acute Lung Injury by a Novel CD14-Inhibitory Receptor Activator of the NF- κ B Ligand Peptide in Mice. <i>ImmunoHorizons</i> , 2021, 5, 438-447.	0.8	5
119	Future Directions of Therapeutic Vaccines for Chronic Diseases. <i>Circulation Journal</i> , 2020, 84, 1895-1902.	0.7	5
120	Blood pressure fluctuations and the indoor environment in a highly insulated and airtight model house during the cold winter season. <i>Hypertension Research</i> , 2022, 45, 1217-1219.	1.5	5
121	Peptide vaccine for semaphorin3E ameliorates systemic glucose intolerance in mice with dietary obesity. <i>Scientific Reports</i> , 2019, 9, 3858.	1.6	4
122	Development of an IL-17A DNA Vaccine to Treat Systemic Lupus Erythematosus in Mice. <i>Vaccines</i> , 2020, 8, 83.	2.1	4
123	Management guideline for Werner syndrome 2020 1. Dyslipidemia and fatty liver associated with Werner syndrome. <i>Geriatrics and Gerontology International</i> , 2021, 21, 133-138.	0.7	4
124	Development of anti-thrombotic vaccine against human S100A9 in rhesus monkey. <i>Scientific Reports</i> , 2021, 11, 11472.	1.6	4
125	Prevention of vascular dementia via immunotherapeutic blockade of renin-angiotensin system in a rat model. <i>Brain Research</i> , 2021, 1772, 147667.	1.1	4
126	Development of DNA vaccines as an anti-hypertensive therapy or for anti-angiogenesis. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 431-436.	1.4	3

#	ARTICLE	IF	CITATIONS
127	Novel properties of myoferlin in glucose metabolism via pathways involving modulation of adipose functions. <i>FASEB Journal</i> , 2020, 34, 2792-2811.	0.2	3
128	Management guideline for <sc>W</sc>erner syndrome 2020. <sc>5</sc>. <sc>I</sc>nfection associated with <sc>W</sc>erner syndrome. <i>Geriatrics and Gerontology International</i> , 2021, 21, 150-152.	0.7	3
129	A novel angiotensin II peptide vaccine without an adjuvant in mice. <i>Journal of Hypertension</i> , 2021, 39, 181-189.	0.3	3
130	RANKL Impairs the TLR4 Pathway by Increasing TRAF6 and RANK Interaction in Macrophages. <i>BioMed Research International</i> , 2022, 2022, 1-13.	0.9	3
131	Research for Localized High-Efficient Gene Transfer by the Magnetic Force Control Using High Temperature Superconducting Bulk Magnet. <i>IEEE Transactions on Applied Superconductivity</i> , 2014, 24, 1-5.	1.1	2
132	A novel lipoprotein (a) lowering drug, D-47, decreases neointima thickening after vascular injury. <i>Journal of Medical Investigation</i> , 2017, 64, 64-67.	0.2	2
133	AJP001, a novel helper T cell epitope, induces a humoral immune response with activation of innate immunity when included in a peptide vaccine. <i>FASEB BioAdvances</i> , 2019, 1, 760-772.	1.3	2
134	Pathophysiological significance of cylindromatosis in the vascular endothelium and macrophages for the initiation of age-related atherogenesis. <i>Biochemical and Biophysical Research Communications</i> , 2019, 508, 1168-1174.	1.0	2
135	Effect of prorenin peptide vaccine on the early phase of diabetic retinopathy in a murine model of type 2 diabetes. <i>PLoS ONE</i> , 2022, 17, e0262568.	1.1	2
136	A novel soluble epoxide hydrolase vaccine protects murine cardiac muscle against myocardial infarction. <i>Scientific Reports</i> , 2022, 12, 6923.	1.6	2
137	Evaluation of the Genetic Risk of Hypertension-Related Diseases. <i>Circulation Journal</i> , 2015, 79, 756-757.	0.7	1
138	Favorable effects of statins beyond lipid lowering. <i>Future Lipidology</i> , 2006, 1, 75-80.	0.5	0
139	Cold shock domain protein A, novel endogenous regulator of angiogenesis in heart. <i>Journal of Molecular and Cellular Cardiology</i> , 2008, 45, S7-S8.	0.9	0
140	Can Forkhead Box P1 be a novel therapeutic target for atherosclerosis?. <i>Atherosclerosis</i> , 2011, 218, 26-27.	0.4	0
141	A Model of Stroke and Vascular Injury in the Brain. , 2016, , 263-274.		0
142	A vaccine targeting blood clot formation: what is the potential?. <i>Expert Review of Vaccines</i> , 2019, 18, 419-421.	2.0	0
143	Development of anti-thrombotic and hypertensive vaccine for prevention of ischemic stroke. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2021, 32, 284-288.	0.1	0
144	Study protocol for a randomized, open-label, non-controlled Phase I/II Study to assess safety and immunogenicity of twice or three times dosing of intramuscular COVID-19 DNA vaccine in healthy adults. <i>Translational and Regulatory Sciences</i> , 2021, , .	0.2	0

#	ARTICLE	IF	CITATIONS
145	Molecular mechanism of vascular calcification with aging. Japanese Journal of Thrombosis and Hemostasis, 2015, 26, 284-289.	0.1	0
146	Vaccines and Biologics for Hypertension and Diabetes. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY39-2.	0.0	0
147	Closing: Clinical Applications of Therapeutic Vaccines in the Near Future. , 2019, , 73-79.		0
148	A Vaccine for Ischemic Stroke. , 2019, , 21-32.		0